Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Tax Provisions (2019 - 2023)

Historic Tax Provisions for Coherus Oncology (CHRS) over the last 3 years, with Q3 2023 value amounting to -$380000.0.

  • Coherus Oncology's Tax Provisions changed N/A to -$380000.0 in Q3 2023 from the same period last year, while for Dec 2023 it was -$380000.0, marking a year-over-year change of. This contributed to the annual value of -$380000.0 for FY2023, which is N/A changed from last year.
  • Latest data reveals that Coherus Oncology reported Tax Provisions of -$380000.0 as of Q3 2023.
  • Coherus Oncology's 5-year Tax Provisions high stood at $2.0 million for Q4 2019, and its period low was -$380000.0 during Q3 2023.
  • Moreover, its 3-year median value for Tax Provisions was $890000.0 (2019), whereas its average is $760500.0.
  • Over the last 5 years, Coherus Oncology's Tax Provisions had its largest YoY gain of 244901.96% in 2020, and its largest YoY loss of 7638.72% in 2020.
  • Over the past 3 years, Coherus Oncology's Tax Provisions (Quarter) stood at $2.0 million in 2019, then tumbled by 46.72% to $1.1 million in 2020, then plummeted by 134.89% to -$380000.0 in 2023.
  • Its Tax Provisions was -$380000.0 in Q3 2023, compared to $1.1 million in Q4 2020 and $200000.0 in Q3 2020.